PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
Journal
Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: Sweden
ID NLM: 8709065
Informations de publication
Date de publication:
23 May 2024
23 May 2024
Historique:
received:
22
12
2023
accepted:
12
04
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
23
5
2024
Statut:
epublish
Résumé
In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful. PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe. PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients. ble from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024. European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
Sections du résumé
BACKGROUND
BACKGROUND
In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful.
PATIENTS AND METHODS
METHODS
PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe.
RESULTS
RESULTS
PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024.
CONCLUSION
CONCLUSIONS
European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients. ble from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024.
CONCLUSION
CONCLUSIONS
European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.
Identifiants
pubmed: 38779910
doi: 10.2340/1651-226X.2024.34791
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
385-391Investigateurs
Adriana Boata
(A)
Agnieszka Janowska
(A)
Aida Sarmiento-Castro
(A)
Alba López Rioja
(A)
Albrecht Stenzinger
(A)
Ali Razzak
(A)
Anders Edsjö
(A)
Anni Lepland
(A)
Annika Baan
(A)
Antonio Marra
(A)
Anu Planken
(A)
Arnoldo Frigessi
(A)
Åslaug Helland
(Å)
Attila Patocs
(A)
Atse Huisman
(A)
Beatrice Mainoli
(B)
Bettina Ryll
(B)
Bianca Cucoș
(B)
Birute Brasiuniene
(B)
Christina Kawati Stenberg
(C)
Claire L Hyder
(CL)
Cosmina Cioroboiu
(C)
Daniel Kazdal
(D)
David Tamborero
(D)
Dora Cerina
(D)
Douwe Postmus
(D)
Ebba Hallersjö Hult
(E)
Edita Baltruškevičienė
(E)
Eduard Vrdoljak
(E)
Edvard Abel
(E)
Egbert Smit
(E)
Eivind Hovig
(E)
Elena Chavarria
(E)
Elena Garralda
(E)
Eline Aas
(E)
Elisa Bjørgo
(E)
Emile Voest
(E)
Emilie van der Sande
(E)
Femke Verwer
(F)
Francesco Pignatti
(F)
Giuseppe Curigliano
(G)
Gro Live Fagereng
(G)
Haiko Bloemendal
(H)
Hans Gelderblom
(H)
Hans Timmer
(H)
Hege G Russnes
(HG)
Henk Verheul
(H)
Irene Brana
(I)
Iwona Lugowska
(I)
Janne Lehtiö
(J)
Jean-Yves Blay
(JY)
Julien Bollard
(J)
Julio Oliveira
(J)
Kadri Rekker
(K)
Kadri Toome
(K)
Katarina Steen Carlsson
(K)
Katarzyna Kulbacka-Ortiz
(K)
Kate Duffus
(K)
Katriina Jalkanen
(K)
Kjetil Taskén
(K)
Knut Smeland
(K)
Kristiina Ojamaa
(K)
Kristoffer Staal Rohrberg
(KS)
Loic Verlingue
(L)
Maeve A Lowery
(MA)
Manon Antouly
(M)
Marius Geanta
(M)
Matthew G Krebs
(MG)
Mika Mustonen
(M)
Oskar Frisell
(O)
Paola Zagami
(P)
Peter Grell
(P)
Péter Nagy
(P)
Peter Nygren
(P)
Peter Asplund
(P)
Ragnhild Sørum Falk
(R)
Ralf Herold
(R)
Rasa Sabaliauskaite
(R)
Richard Rosenquist
(R)
Rui Henrique
(R)
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani
(S)
Sarah Halford
(S)
Sarah Mellor
(S)
Sigmund Brabrand
(S)
Simon Ekman
(S)
Soemeya F Haj Mohammad
(SF)
Sonata Jarmalaite
(S)
Stephen Nabarro
(S)
Tanja Juslin
(T)
Tiina Kahre
(T)
Tina Kringelbach
(T)
Tormod Guren
(T)
Ulrik Lassen
(U)
Vince Kornél Grolmusz
(VK)
Xenia Villalobos Alberu
(X)